Full Text View
Tabular View
No Study Results Posted
Related Studies
Study to Evaluate the Safety of AT2220 in Pompe Disease
This study has been terminated.
Study NCT00688597   Information provided by Amicus Therapeutics
First Received: May 30, 2008   Last Updated: November 9, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Pompe Disease
Additional conditions recognized in this trial
Glycogen Storage Disease Type II
More general conditions related to this trial
Brain Diseases
Brain Diseases, Metabolic
Brain Diseases, Metabolic, Inborn
Carbohydrate Metabolism, Inborn Errors
Central Nervous System Diseases
Genetic Diseases, Inborn
Glycogen Storage Disease
Lysosomal Storage Diseases
Lysosomal Storage Diseases, Nervous System
Metabolic Diseases
Metabolism, Inborn Errors
Nervous System Diseases
Interventions listed in this trial
AT2220
Sponsors listed in this trial
Amicus Therapeutics


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services